The growth hormone/insulin-like growth factor-I system in chronic heart failure and its interaction with adiponectin

European Journal of Heart Failure

Volumn 12, Issue 11, 2010, Pages 1154-1155

  Andreassen, Mikkel ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL PROLIFERATION; DISEASE COURSE; DISEASE SEVERITY; GROWTH HORMONE DEFICIENCY; HEART FAILURE; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; LIPID METABOLISM; METABOLIC SYNDROME X; MORTALITY; NOTE; OBESITY; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ADIPONECTIN; HEART FAILURE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; PROGNOSIS;

EID: 77958562296     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq173     Document Type: Note

References (20)

1. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 2008;69:347-358.
2. Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D, Wilson PW. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003;139:642-648.
3. Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LO. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol 2009;160:25-31.
4. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829-1837.
5. Andreassen M, Kistorp C, Raymond I, Hildebrandt P, Gustafsson F, Kristensen LO, Faber J. Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure. Growth Horm IGF Res 2009;19:486-490.
6. Al-Obaidi MK, Hon JK, Stubbs PJ, Barnes J, Amersey RA, Dahdal M, Laycock JF, Noble MI, Alaghband-Zadeh J. Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure. Am Heart J 2001;142:E10.
7. Hassfeld S, Eichhorn C, Stehr K, Naegele H, Geier C, Steeg M, Ranke MB, Oezcelik C, Osterziel KJ. Insulin-like growth factor-binding proteins 2 and 3 are independent predictors of a poor prognosis in patients with dilated cardiomyopa-thy. Heart 2007;93:359-360.
8. Petretta M, Colao A, Sardu C, Scopacasa F, Marzullo P, Pivonello R, Fontanella L, De Caterina CM, De Simone SA, Bonaduce D. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 2007;17:288-296.
9. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003;13:113-170.
10. Juul A, Flyvbjerg A, Frystyk J, Muller J, Skakkebaek NE. Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins-1 and-3 and IGFBP-3 protease activity in boys with normal or precocious puberty. Clin Endo-crinol (Oxf) 1996;44:515-523.
11. Watanabe S, Tamura T, Ono K, Horiuchi H, Kimura T, Kita T, Furukawa Y. Insulinlike growth factor axis (IGF-I/IGFBP3) as a prognostic predictor of heart failure: Association with adiponectin. Eur J Heart Fail 2010;12:1214-1222.
12. Lee WL, Chen JW, Ting CT, Ishiwata T, Lin SJ, Korc M, Wang PH. Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of car-diomyocytes in dilated cardiomyopathy. Endocrinology 1999;140:4831-4840.
13. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, Santeusanio F, Porcellati C, Brunetti P. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999;100:1802-1807.
14. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res 2000;86:125-130.
15. Thum T, Fleissner F, Klink I, Tsikas D, Jakob M, Bauersachs J, Stichtenoth DO. Growth hormone treatment improves markers of systemic nitric oxide bioavail-ability via insulin-like growth factor-I. J Clin Endocrinol Metab 2007;92:4172-4179.
16. Schulze PC, Spate U. Insulin-like growth factor-1 and muscle wasting in chronic heart failure. Int J Biochem Cell Biol 2005;37:2023-2035.
17. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
18. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-1762.
19. Sucunza N, Barahona MJ, Resmini E, Fernandez-Real JM, Ricart W, Farrerons J, Rodriguez EJ, Marin AM, Puig T, Webb SM. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 2009;94:3889-3896.
20. Kanety H, Hemi R, Ginsberg S, Pariente C, Yissachar E, Barhod E, Funahashi T, Laron Z. Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity. Eur J Endocrinol 2009;161:837-844.